天津医药

天津医药 ›› 2015, Vol. 43 ›› Issue (1): 97-101.doi: 10.3969/j.issn.0253-9896.2015.01.026

• 循证医学 • 上一篇    下一篇

E-钙黏蛋白基因启动子区甲基化与膀胱癌关联性的#br# Meta 分析#br#

张书卿， 张绪亮， 张博， 洪亮#br# #br#   

  1. 湖北省黄石市中心医院普爱病区肿瘤外科（邮编 435000）
  • 收稿日期:2014-05-15 修回日期:2014-08-01 出版日期:2015-01-15 发布日期:2015-01-30
  • 作者简介:张书卿（1980）， 男， 主治医师， 学士， 主要从事胸腹部肿瘤的基础与临床研究

Role of E-cadherin gene promoter methylation in bladder carcinogenesis: a Meta-analysis

ZHANG Shuqing, ZHANG Xuliang, ZHANG Bo, HONG Liang#br# #br#   

  1. Department of Surgical Oncology, Huangshi Central Hospital, Huangshi 435000, China

  • Received:2014-05-15 Revised:2014-08-01 Published:2015-01-15 Online:2015-01-30

PDF (PC)

3813

摘要： 摘要： 目的 将既往有关 E-钙黏蛋白（CDH1）基因启动子区甲基化与膀胱癌关系的研究进行 Meta 分析， 评估 CDH1 基因启动子区甲基化与膀胱癌的具体关联。 方法 参照 Cochrane 协作网制定的检索策略在国内外相关数据库进行检索， 筛选并纳入文献后， 提取文献信息： 第一作者、文献发表时间、国家、语种、研究设计、样本量、种族、病理亚型、甲基化检测方法、基因甲基化频率等。 采用 STATA12.0 进行 Meta 分析， 计算优势比（OR）及其 95%可信区间（95%CI）。 结果 本 Meta 分析共计纳入 10 项病例对照研究， 通过检测其中 620 例膀胱癌组织和 341 例正常或癌旁组织的 CDH1 基因甲基化频率， 结果发现膀胱癌组织中的甲基化频率明显高于正常或癌旁组织（OR=3.09， 95%CI： 1.13～ 8.50， P=0.029）； 亚组分析结果显示， 在亚洲人群中膀胱癌组织中的甲基化频率明显高于正常或癌旁组织（OR= 3.85， 95%CI： 1.46~10.14， P=0.006）， 而在欧美人群中未发现此种差异（OR=2.22， 95%CI： 0.38~12.91， P=0.375）； 采用 MSP 方法检测时， 膀胱癌组织与癌旁及正常组织间 CDH1 基因启动子区甲基化频率存在明显差异（P < 0.001）， 采用 Q-MSP 方法检测时， 两组 CDH1 基因启动子区甲基化频率无明显差异（P=0.818）。 结论 CDH1 基因启动子区甲基化可能参与了膀胱癌的发生和发展。

关键词: E-钙黏蛋白, 甲基化, 膀胱癌, Meta 分析

Abstract: Abstract： Objective To assess the role of E-cadherin (CDH1) promoter methylation in bladder carcinogenesis by meta-analysis. Methods The relevant database were searched by the retrieval strategy of Cochrane network. All included studies were collected following data: the first author’ s surname, publication year of article, country, language of publication, design of study, sample size, ethnicity, histological subtypes, methylation detection method and genotype frequencies etc. This meta-analysis was performed using the STATA 12.0 software. The crude odds ratio (OR) with 95% confidence interval (CI) was calculated. Results Ten case-control studies were included in this meta-analysis. The methylation frequency of CDH1 was detected in 620 bladder cancer tissues and 341 normal or cancerous tissues. Results showed that the methylation frequency of CDH1 was significantly higher in bladder cancer tissue than that of normal or cancerous tissue (OR = 3.09, 95% CI: 1.13~8.50, P = 0.029). Furthermore, the ethnicity-stratified analysis revealed that the methylation frequency of CDH1 was significantly higher in bladder cancer tissue of Asian populations than that of normal or cancerous tissue (OR=3.85, 95% CI: 1.46~10.14, P=0.006), but no such association was found in Caucasian populations（OR=2.22, 95%CI: 0.38-12.91, P= 0.375). The subgroup analysis based on the detection methods revealed that there was a statistically significant difference in the methylation frequency of CDH1 between bladder cancer tissue and adjacent tissues and normal tissues under the MSP subgroup (P < 0.001), while such association was not observed under the Q-MSP subgroup (P = 0.818). Conclusion Pro⁃ moter methylation of CDH1 gene may be involved in the occurrence and development of bladder cancer, which may serve as a biomarker for diagnosis and prognosis of bladder cancer.

Key words: E-cadherin, methylation, bladder cancer, Meta-analysis